Other pre-emptive approaches involve using antibody–drug conjugates that target residual leukaemia cells such as inotuzumab ozogamicin (an anti-CD22 antibody linked to calicheamicin) or moxetumomab pasudotox (an anti-CD22 antibody linked to a Pseudomonas exotoxin). Here, CD22 is linked to leukemia.